Global Osteogenesis Imperfecta Treatment Market, By Drugs (Teriparatide, Denosumab, and Others) By Route of Administration (Subcutaneous, Intravenous, Oral, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 722.8 Million in 2023 and is expected to exhibit a CAGR of 2.4% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The key market players are focused on adopting growth strategies such as collaboration as well as acquisition, which will drive the global osteogenesis imperfecta treatment market during the forecast period. For instance, in June 2022, Sirana Pharma GmbH, a biotechnology company focusing on the development of innovative and effective treatments for unmet medical needs in muscle and bone diseases, announced a collaborative research agreement with Pfizer Inc., a multinational pharmaceutical and biotechnology company to investigate the potential identification and validation of a novel treatment concept for a rare bone disease osteogenesis imperfecta. The collaboration will utilize Sirana’s proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.
Global Osteogenesis Imperfecta Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global osteogenesis imperfecta treatment market due to the delayed in the treatment of osteogenesis imperfecta. The COVID-19 pandemic resulted in the cancellation or delay of all osteogenesis imperfecta treatment procedures. For instance, in January 04 2023, according to a study published in the Journal of Family Medicine and Primary Care published by Frontiers Media S.A, in the 2020 survey, of the 110 respondents, 69 (63%) had at least one appointment delayed due to the lockdown, compared with 89 of the 124 respondents (72%) in 2021. Of the 110 respondents in 2020, 57 (52%) had a remote consultation, increasing to 92 of 124 (74%) in the follow-up survey. In the 2020 survey 63 of 91 respondents (69%) expressed anxiety due to lockdown, compared with 76 of 124 (61%) in 2021. The percentage of total respondents expressing a preference for remote consultation was 48% in 2020, increasing to 71% in 2021. The effects of Covid-19, alongside appointment delays, have increased as the pandemic progresses.
Global Osteogenesis Imperfecta Treatment Market: Key Developments
In June 2022, OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced they have entered an agreement to acquire Pega Medical, a company specializing in the design, development, evaluation and manufacturing of medical devices including its Fassier-Duval Telescopic Intramedullary System designed for patients suffering from Osteogenesis Imperfecta and other bone deformities. OrthoPediatrics will acquire Pega Medical in a transaction valued up to US$ 33 million. Under the terms of the agreement, OrthoPediatrics will acquire Pega Medical for an upfront cash payment of US$ 31 million plus US$ 2 million in stock– which includes certain restrictions for three years.
In August 2022, Quince Therapeutics, a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, presented preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. NOV004 is a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. By improving fracture site accumulation and retention, NOV004 stimulates a robust healing response in preclinical studies of healthy normal, diabetic, osteoporotic, and OI in vivo models. During its OI 2022 presentation titled “Fracture-targeted Anabolics for Treatment of Osteogenesis Imperfecta Fractures,” the company highlighted several preclinical results demonstrating the efficacy of NOV004 in fractures induced in the OI in vivo experiments
Browse 32 Market Data Tables and 25 Figures spread through 220 Pages and in-depth TOC on “Global Osteogenesis Imperfecta Treatment Market”- Forecast to 2030, Global Osteogenesis Imperfecta Treatment Market, By Drugs (Teriparatide, Denosumab, and Others) By Route of Administration (Subcutaneous, Intravenous, Oral, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/osteogenesis-imperfecta-treatment-market-4064
Key Takeaways of the Global Osteogenesis Imperfecta Treatment Market:
- The global osteogenesis imperfecta treatment market is expected to exhibit a CAGR of 2.4% during the forecast period. The collaboration with emerging economies offers lucrative growth opportunities for players in the global osteogenesis imperfecta treatment market. For instance, in October 2020, Recombinetics, a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine entered into a collaborative research project with Mayo Clinic. The aim of this collaboration was to advance osteogenesis imperfecta research by developing the first swine models of osteogenesis imperfecta. These models will aid preclinical researchers to better understand the etiology and progression of the disease and thereby, provide a trustworthy preclinical model to establish the safety and efficacy of novel therapies needed by the OI patients.
- Among Drugs, the Denosumab segment is expected to growth in the global osteogenesis imperfecta treatment market over the forecast period, owing due to its the emergence as an important therapy for malignancies and other skeletal disorders, including pediatric skeletal conditions such as OI. For instance, in October 2021, according to an article published in the Journal of Biomolecules, the most common medication used in OI treatment are Denosumab, and bisphosphonates. They provide promising strategies for the future treatment of OI and other genetic bone diseases are based on stem cell transplantation, genetic engineering, and molecular chaperones usage.
- Among Route of Administration, the intravenous segment is expected to hold a dominant position in the global osteogenesis imperfecta treatment market during the forecast period and this is attributed due to its faster onset of action and ability to reduce the incidence of fracture and increases bone mineral density (BMD). For instance, in February 2021, according to an article published by the American Society of Health-System Pharmacists, Teriparatide injection is used to treat osteogenesis imperfecta (a condition in which the bones break easily) in women who have undergone menopause, who are at high risk of fractures (broken bones), and cannot use other osteogenesis imperfecta treatments.
- Major players operating in the global osteogenesis imperfecta treatment market include BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
